[Advances in differential diagnosis and treatment of patients with sarcoidosis].

The implementation of treatment in patients with sarcoidosis (SA) must be associated with the certainty of diagnosis, which is difficult due to the lack of unambiguous criteria. Finding the presence of noncaseating granulomas in bioptic material is not always indicative of SA. The main point of SA's diagnosis is the level of its activity, because only patients in the active stage should be qualified for treatment. In therapy, glucocorticosteroids or second-line drugs - methotrexate or azathioprine are still recommended. Introduced monoclonal antibodies (infliximab, etanercept, adaluimumab, golimumab, rituximab), tested for efficacy in other pathologies associated with the formation of granulomas, have a limited application in patients with SA. In contrast, anti-fibrotics (pirfenidone and nintedanib) are in clinical trials. The latest method of controlling the fibrosis of the parenchyma in the course of SA is the use of mesenchymal cells obtained from umbilical cord blood. Preliminary results indicate a real possibility of using this therapy in patients with SA.